MedTrace Logo

Use of Topotecan in Patients With Refractory Acute Leukemia

NCT00100477 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2013-09-25

No results posted yet for this study

Summary

The purpose of this study is to identify the highest tolerated doses in drugs used to treat aggressive leukemia, lymphoma or multiple myeloma not responding to standard chemotherapy treatment. The drugs being used in this study include drugs frequently used in treating such diseases (mitoxantrone and etoposide) as well as a newer drug that has also been shown to be effective (topotecan).

Conditions

Interventions

DRUG

Topotecan

DRUG

Mitozantrone

DRUG

Etoposide

Sponsors & Collaborators

Principal Investigators

  • Mark Mainwaring · North Florida/South Georgia Veterans Health System

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-08-31
Primary Completion
2001-01-31
Completion
2001-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00100477 on ClinicalTrials.gov